ATE231143T1 - Triarylimidazole - Google Patents

Triarylimidazole

Info

Publication number
ATE231143T1
ATE231143T1 AT00930101T AT00930101T ATE231143T1 AT E231143 T1 ATE231143 T1 AT E231143T1 AT 00930101 T AT00930101 T AT 00930101T AT 00930101 T AT00930101 T AT 00930101T AT E231143 T1 ATE231143 T1 AT E231143T1
Authority
AT
Austria
Prior art keywords
triarylimidazole
andone
6alkyl
chr
pharmaceuticals
Prior art date
Application number
AT00930101T
Other languages
English (en)
Inventor
Joelle Lorraine Burgess
James Francis Callahan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE231143T1 publication Critical patent/ATE231143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
AT00930101T 1999-04-09 2000-04-06 Triarylimidazole ATE231143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12868799P 1999-04-09 1999-04-09
PCT/US2000/009147 WO2000061576A1 (en) 1999-04-09 2000-04-06 Triarylimidazoles

Publications (1)

Publication Number Publication Date
ATE231143T1 true ATE231143T1 (de) 2003-02-15

Family

ID=22436501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00930101T ATE231143T1 (de) 1999-04-09 2000-04-06 Triarylimidazole

Country Status (9)

Country Link
US (1) US6465493B1 (de)
EP (1) EP1169317B1 (de)
JP (1) JP2002541253A (de)
AT (1) ATE231143T1 (de)
AU (1) AU4798000A (de)
CO (1) CO5031285A1 (de)
DE (1) DE60001229T2 (de)
ES (1) ES2187473T3 (de)
WO (1) WO2000061576A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JP2004510696A (ja) * 2000-05-19 2004-04-08 アメリカ合衆国 線維症の防止および創傷治癒の改善のためのＳｍａｄ３の阻害
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0100762D0 (en) * 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
IL158512A0 (en) 2001-05-24 2004-05-12 Lilly Co Eli Novel pyrrole derivatives as pharmaceutical agents
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
ATE343572T1 (de) 2002-08-09 2006-11-15 Lilly Co Eli Benzimidazole und benzothiazole als inhibitoren der map-kinase
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
CA2499429C (en) 2002-09-18 2010-09-21 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
AU2003260810A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
AP2005003262A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.
KR20050057392A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
WO2004060362A2 (en) * 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JPWO2004108160A1 (ja) * 2003-06-05 2006-07-27 日本新薬株式会社 骨形成促進増強剤及びそのスクリーニング方法
AU2004274326B2 (en) 2003-09-17 2011-11-17 Sumitomo Chemical Company, Limited Cinnamoyl derivatives and use thereof
JP4815773B2 (ja) * 2003-09-17 2011-11-16 住友化学株式会社 シンナモイル化合物及びその用途
JP2006104061A (ja) * 2003-09-17 2006-04-20 Sumitomo Chemical Co Ltd シンナモイル化合物含有ｉ型コラーゲン遺伝子転写抑制組成物。
RU2367661C2 (ru) 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AU2005280496B2 (en) * 2004-07-29 2009-10-08 Schering-Plough Pty. Limited Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
JP2009501236A (ja) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
EP2077838B1 (de) 2006-10-25 2013-04-03 The Rockefeller University Verfahren zur behandlung von amyloid-beta verwandten erkrankungen und zusammensetzungen dafür
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
WO2008094556A2 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
CA2686318A1 (en) * 2007-05-04 2008-11-13 Jana Pickova Compound feed for aquaculture
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
MX2009012558A (es) 2007-08-03 2010-04-21 Biomarin Iga Ltd Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US9446175B2 (en) * 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
KR101938368B1 (ko) 2011-07-13 2019-01-14 주식회사 티움바이오 Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸
US9637723B2 (en) 2012-05-30 2017-05-02 Cornell University Q Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
SI2880053T1 (sl) 2012-08-01 2020-08-31 Ikaika Therapeutics, Llc Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4
US20140242595A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CA2914615C (en) 2013-06-05 2023-10-17 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
BR112016016098A2 (pt) 2014-01-09 2017-08-08 Intracellular Therapies Inc Compostos orgânicos
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
EP3133149B1 (de) 2014-04-18 2022-06-22 Kyoto Prefectural Public University Corporation Verfahren zur herstellung von osteoblasten und osteoblasteninduktor
US20170107486A1 (en) 2014-04-21 2017-04-20 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3741397A1 (de) 2015-12-11 2020-11-25 Research Institute at Nationwide Children's Hospital Systeme und verfahren für optimierte patientenspezifische gewebegezüchtete gefässtransplantate
EP3897689A1 (de) 2018-12-21 2021-10-27 Northwestern University Verwendung von annexinen zur vorbeugung und behandlung von muskelmembranverletzungen
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
CN115052663A (zh) 2020-01-08 2022-09-13 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
US20240018122A1 (en) 2020-07-15 2024-01-18 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
BR112023000592A2 (pt) 2020-07-15 2023-01-31 Chiesi Farm Spa Derivados de pirido oxazina amino como inibidores de alk5
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB138101A (de)
CH561202A5 (de) * 1971-05-10 1975-04-30 Ciba Geigy Ag
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
DE69433501T2 (de) 1993-11-08 2004-11-04 Smithkline Beecham Corp. Oxazole zur behandlung von zytokinvermittelten erkrankungen
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
CA2271893A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles as glucagon antagonists
JPH11180958A (ja) * 1997-12-24 1999-07-06 Yamanouchi Pharmaceut Co Ltd 新規アミン誘導体

Also Published As

Publication number Publication date
DE60001229D1 (de) 2003-02-20
WO2000061576A1 (en) 2000-10-19
US6465493B1 (en) 2002-10-15
CO5031285A1 (es) 2001-04-27
JP2002541253A (ja) 2002-12-03
EP1169317A1 (de) 2002-01-09
AU4798000A (en) 2000-11-14
EP1169317B1 (de) 2003-01-15
DE60001229T2 (de) 2003-10-30
ES2187473T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
ATE231143T1 (de) Triarylimidazole
CO5280078A1 (es) Compuestos
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA03002911A (es) Compuestos quimicos.
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
AU2001266575A1 (en) Chemical compounds
MXPA02012076A (es) Compuestos quimicos.
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE60112960D1 (de) Kondensierte pyridoindolderivate
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
ATE213241T1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
ATE286887T1 (de) Antibakterielle mittel
SE9901901D0 (sv) Compounds
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
IL159493A0 (en) Pharmaceutical formulation containing an ltb4 antagonist
SE9603284D0 (sv) New compounds
SE9802650D0 (sv) Compounds
TR200100476T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties